Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + transcatheter arterial chemoembolization
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial
01
Overview
Anlotinib is a novel small-molecule multi-kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR1/2/3), fibroblast growth factor receptors (FGFR1/2/3/4), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit. Developed by Chia Tai Tianqing Pharmaceutical Group, it functions as an anti-angiogenic and anti-tumor agent. In the context of the ALTER-H004 trial, anlotinib is being evaluated in combination with transcatheter arterial chemoembolization (TACE) as an adjuvant therapy for patients with advanced hepatocellular carcinoma (HCC) who are at high risk of recurrence following surgical resection. The regimen typically involves a TACE procedure followed by oral administration of anlotinib hydrochloride.
- Brand names
- Fukanghua
- Other names
- anlotinib hydrochlorideTACE
02
Targets
FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on anlotinib + transcatheter arterial chemoembolization.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + transcatheter arterial chemoembolization.